{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=unfractionated+heparin&page=6",
    "query": {
      "intervention": "unfractionated heparin",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 445,
    "total_pages": 45,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=unfractionated+heparin&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=unfractionated+heparin&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T05:55:31.857Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00041782",
      "title": "Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Deep Vein Thrombosis"
      ],
      "interventions": [
        {
          "name": "Dalteparin (Fragmin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2000-10",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2018-10-31",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00041782"
    },
    {
      "nct_id": "NCT00321009",
      "title": "LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Acute Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corewell Health East",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2000-03",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2006-05-03",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Royal Oak, Michigan • Syracuse, New York + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Royal Oak",
          "state": "Michigan"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        },
        {
          "city": "Doylestown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00321009"
    },
    {
      "nct_id": "NCT01828697",
      "title": "Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Deep Venous Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Low dose nadroparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose nadroparin",
          "type": "DRUG"
        },
        {
          "name": "Low dose enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Low dose dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose dalteparin",
          "type": "DRUG"
        },
        {
          "name": "Fixed low dose tinzaparin",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose tinzaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 1110,
      "start_date": "2013-04-24",
      "completion_date": "2021-10-31",
      "has_results": false,
      "last_update_posted_date": "2022-05-26",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828697"
    },
    {
      "nct_id": "NCT00715455",
      "title": "Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "REG1",
          "type": "DRUG"
        },
        {
          "name": "Unfractionated Heparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regado Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 26,
      "start_date": "2007-10",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2013-05-31",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 5,
      "location_summary": "Indianapolis, Indiana • Detroit, Michigan • Chapel Hill, North Carolina + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Danville",
          "state": "Pennsylvania"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00715455"
    },
    {
      "nct_id": "NCT01583218",
      "title": "Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism (VTE)"
      ],
      "interventions": [
        {
          "name": "Betrixaban",
          "type": "DRUG"
        },
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Portola Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 7513,
      "start_date": "2012-03",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2023-08-07",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 75,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01583218"
    },
    {
      "nct_id": "NCT01576055",
      "title": "Evaluation of the GORE TIGRIS Vascular Stent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Arterial Disease"
      ],
      "interventions": [
        {
          "name": "TIGRIS Vascular Stent",
          "type": "DEVICE"
        },
        {
          "name": "BARD LifeStent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "W.L.Gore & Associates",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2012-04",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2017-10-09",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 34,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Oceanside, California + 30 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01576055"
    },
    {
      "nct_id": "NCT00135876",
      "title": "Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Brain Tumors"
      ],
      "interventions": [
        {
          "name": "dalteparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ontario Clinical Oncology Group (OCOG)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2002-10",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2007-04-27",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 3,
      "location_summary": "Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135876"
    },
    {
      "nct_id": "NCT03113721",
      "title": "Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sepsis",
        "Septic Shock",
        "Sepsis With Acute Organ Dysfunction"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Axis Shield Diagnostics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 571,
      "start_date": "2017-03-27",
      "completion_date": "2019-03-01",
      "has_results": false,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 5,
      "location_summary": "Philadelphia, Pennsylvania • York, Pennsylvania • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "York",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03113721"
    },
    {
      "nct_id": "NCT05853042",
      "title": "MERITnI - Mindray-hs-cTnI Assay: Analytical and Clinical Evaluation for the Diagnosis and RIsk AssessmenT of Myocardial InfarctIon.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myocardial Infarction",
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "high-sensitivity cardiac troponin testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Fred Apple",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 1559,
      "start_date": "2022-12-12",
      "completion_date": "2025-07-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05853042"
    },
    {
      "nct_id": "NCT04512079",
      "title": "FREEDOM COVID-19 Anticoagulation Strategy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Enoxaparin",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valentin Fuster",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3460,
      "start_date": "2020-09-08",
      "completion_date": "2022-12-30",
      "has_results": false,
      "last_update_posted_date": "2023-03-16",
      "last_synced_at": "2026-10-09T05:55:31.857Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04512079"
    }
  ]
}